These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 31848884)

  • 21. Biological and clinical consequences of NPM1 mutations in AML.
    Heath EM; Chan SM; Minden MD; Murphy T; Shlush LI; Schimmer AD
    Leukemia; 2017 Apr; 31(4):798-807. PubMed ID: 28111462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
    Au CH; Wa A; Ho DN; Chan TL; Ma ES
    Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
    Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
    [No Abstract]   [Full Text] [Related]  

  • 24. Contemporary Management of Acute Myeloid Leukemia: A Review.
    Venugopal S; Sekeres MA
    JAMA Oncol; 2024 Oct; 10(10):1417-1425. PubMed ID: 39115831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute myeloid leukemia transformed to a targetable disease.
    Saleh K; Khalifeh-Saleh N; Kourie HR
    Future Oncol; 2020 May; 16(14):961-972. PubMed ID: 32297538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
    Shapiro RM; Kim DDH
    Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.
    Selim AG; Moore AS
    J Mol Diagn; 2018 Jul; 20(4):389-397. PubMed ID: 29689379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia.
    Patel SS; Pinkus GS; Ritterhouse LL; Segal JP; Dal Cin P; Restrepo T; Harris MH; Stone RM; Hasserjian RP; Weinberg OK
    Am J Hematol; 2019 Aug; 94(8):921-928. PubMed ID: 31148220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.
    Yu T; Chi J; Wang L
    Hematology; 2021 Dec; 26(1):848-859. PubMed ID: 34674615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?
    Petrova L; Vrbacky F; Lanska M; Zavrelova A; Zak P; Hrochova K
    Clin Biochem; 2018 Nov; 61():34-39. PubMed ID: 30176240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.
    Mason EF; Hasserjian RP; Aggarwal N; Seegmiller AC; Pozdnyakova O
    Blood Adv; 2019 Nov; 3(21):3322-3332. PubMed ID: 31698462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.
    Lin PH; Li HY; Fan SC; Yuan TH; Chen M; Hsu YH; Yang YH; Li LY; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Lin CH; Lien MY; Chen TT; Ni YH; Chiu CF
    Cancer Med; 2017 Feb; 6(2):349-360. PubMed ID: 28070990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia.
    Kim JJ; Jang JE; Lee HA; Park MR; Kook HW; Lee ST; Choi JR; Min YH; Shin S; Cheong JW
    Ann Lab Med; 2023 Jul; 43(4):328-336. PubMed ID: 36843401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status and trends in the diagnostics of AML and MDS.
    Shumilov E; Flach J; Kohlmann A; Banz Y; Bonadies N; Fiedler M; Pabst T; Bacher U
    Blood Rev; 2018 Nov; 32(6):508-519. PubMed ID: 29728319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients.
    Zuffa E; Franchini E; Papayannidis C; Baldazzi C; Simonetti G; Testoni N; Abbenante MC; Paolini S; Sartor C; Parisi S; Marconi G; Cattina F; Bochicchio MT; Venturi C; Ottaviani E; Cavo M; Martinelli G
    Oncotarget; 2015 Oct; 6(31):31284-94. PubMed ID: 26384303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.
    Onecha E; Linares M; Rapado I; Ruiz-Heredia Y; Martinez-Sanchez P; Cedena T; Pratcorona M; Oteyza JP; Herrera P; Barragan E; Montesinos P; Vela JAG; Magro E; Anguita E; Figuera A; Riaza R; Martinez-Barranco P; Sanchez-Vega B; Nomdedeu J; Gallardo M; Martinez-Lopez J; Ayala R
    Haematologica; 2019 Feb; 104(2):288-296. PubMed ID: 30093399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
    Xiao W; Petrova-Drus K; Roshal M
    Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.
    Hirsch P; Lambert J; Bucci M; Deswarte C; Boudry A; Lambert J; Fenwarth L; Micol JB; Terré C; Celli-Lebras K; Thomas X; Dombret H; Duployez N; Preudhomme C; Itzykson R; Delhommeau F
    Blood Cancer J; 2024 Jun; 14(1):97. PubMed ID: 38871702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
    Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
    Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Application of Next Generation Sequencing for AML/MDS Diagnosis and Treatment].
    Cheng HC; Liu SW; Liu Y; Zhao XF; Li W; Qiu L; Ma J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1631-1635. PubMed ID: 29262888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.